Abstract
There has been emerging interest in implementing therapeutic drug monitoring and model-informed precision dosing of β-lactam antibiotics in critically ill patients, including children. Despite a position paper endorsed by multiple international societies that support these efforts in critically ill adults, implementation of β-lactam precision dosing has not been widely adopted. In this review, we highlight what is known about β-lactam antibiotic pharmacokinetics and pharmacodynamics in critically ill children. We also define the knowledge gaps that present barriers to acceptance and implementation of precision dosing of β-lactam antibiotics in critically ill children: a lack of consensus on which subpopulations would benefit most from precision dosing and the uncertainty of how precision dosing changes outcomes. We conclude with opportunities for further research to close these knowledge gaps.
Original language | English (US) |
---|---|
Article number | 1044683 |
Journal | Frontiers in Pharmacology |
Volume | 13 |
DOIs | |
State | Published - Dec 1 2022 |
Funding
STG is supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R35GM146701. KMP is supported by the National Institute of Child Health and Development T32 Cincinnati Pediatric Clinical Pharmacology Training Program (T32HD069054).
Keywords
- beta-lactam antibiotics
- critically ill
- pediatrics
- population pharmacokinetic models
- precision dosing
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)